Sustained	B:C1710261
delivery	I:C1710261
of	O
vincristine	O
inside	O
an	O
orthotopic	O
mouse	O
sarcoma	I:C1522023
model	O
decreases	O
tumor	O
growth	O
.	O

Sustained	O
delivery	I:C1710261
of	O
vincristine	B:C0042679
inside	O
an	O
orthotopic	O
mouse	O
sarcoma	I:C1522023
model	O
decreases	O
tumor	O
growth	O
.	O

Sustained	O
delivery	I:C1710261
of	O
vincristine	O
inside	O
an	O
orthotopic	B:C0574893
mouse	O
sarcoma	I:C1522023
model	O
decreases	O
tumor	O
growth	O
.	O

Sustained	O
delivery	I:C1710261
of	O
vincristine	O
inside	O
an	O
orthotopic	O
mouse	B:C1522023
sarcoma	I:C1522023
model	O
decreases	O
tumor	O
growth	O
.	O

Sarcoma	B:C1261473
accounts	O
for	O
20	O
%	O
of	O
solid	O
tumors	I:C0280100
in	O
children	O
.	O

Sarcoma	O
accounts	O
for	O
20	O
%	O
of	O
solid	B:C0280100
tumors	I:C0280100
in	O
children	O
.	O

Surgery	B:C0543467
has	O
significant	O
morbidity	O
.	O

We	O
hypothesized	O
that	O
delivering	O
chemotherapy	B:C3665472
directly	O
into	O
tumors	O
through	O
sustained	O
release	I:C1710261
silk	O
systems	O
could	O
slow	O
tumor	O
growth	O
.	O

We	O
hypothesized	O
that	O
delivering	O
chemotherapy	O
directly	O
into	O
tumors	B:C0027651
through	O
sustained	O
release	I:C1710261
silk	O
systems	O
could	O
slow	O
tumor	O
growth	O
.	O

We	O
hypothesized	O
that	O
delivering	O
chemotherapy	O
directly	O
into	O
tumors	O
through	O
sustained	B:C1710261
release	I:C1710261
silk	O
systems	O
could	O
slow	O
tumor	O
growth	O
.	O

We	O
hypothesized	O
that	O
delivering	O
chemotherapy	O
directly	O
into	O
tumors	O
through	O
sustained	O
release	I:C1710261
silk	B:C0074529
systems	O
could	O
slow	O
tumor	O
growth	O
.	O

Human	B:C0086418
Ewing	O
sarcoma	I:C0553580
cells	O
A673	I:C0334227
were	O
cultured	O
with	O
vincristine	O
and	O
doxorubicin	O
to	O
determine	O
half	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
.	O

Human	O
Ewing	B:C0553580
sarcoma	I:C0553580
cells	O
A673	I:C0334227
were	O
cultured	O
with	O
vincristine	O
and	O
doxorubicin	O
to	O
determine	O
half	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
.	O

Human	O
Ewing	O
sarcoma	I:C0553580
cells	B:C0334227
A673	I:C0334227
were	O
cultured	O
with	O
vincristine	O
and	O
doxorubicin	O
to	O
determine	O
half	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
.	O

Human	O
Ewing	O
sarcoma	I:C0553580
cells	O
A673	I:C0334227
were	O
cultured	B:C0430400
with	O
vincristine	O
and	O
doxorubicin	O
to	O
determine	O
half	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
.	O

Human	O
Ewing	O
sarcoma	I:C0553580
cells	O
A673	I:C0334227
were	O
cultured	O
with	O
vincristine	B:C0042679
and	O
doxorubicin	O
to	O
determine	O
half	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
.	O

Human	O
Ewing	O
sarcoma	I:C0553580
cells	O
A673	I:C0334227
were	O
cultured	O
with	O
vincristine	O
and	O
doxorubicin	B:C0013089
to	O
determine	O
half	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
.	O

Cells	B:C0334227
were	O
injected	O
into	O
mouse	O
hind	O
leg	I:C1522391
to	O
create	O
orthotopic	O
tumors	O
.	O

Cells	O
were	O
injected	O
into	O
mouse	B:C0025929
hind	O
leg	I:C1522391
to	O
create	O
orthotopic	O
tumors	O
.	O

Cells	O
were	O
injected	O
into	O
mouse	O
hind	B:C1522391
leg	I:C1522391
to	O
create	O
orthotopic	O
tumors	O
.	O

Cells	O
were	O
injected	O
into	O
mouse	O
hind	O
leg	I:C1522391
to	O
create	O
orthotopic	B:C0574893
tumors	O
.	O

Cells	O
were	O
injected	O
into	O
mouse	O
hind	O
leg	I:C1522391
to	O
create	O
orthotopic	O
tumors	B:C0027651
.	O

Tumor	O
volumes	O
were	O
measured	O
using	O
ultrasound	B:C0041618
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	B:C0184661
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	B:C0021107
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	B:C0074529
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	B:C0013089
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	B:C0013089
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	B:C0042679
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	B:C0042679
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	B:C0074529
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	B:C0042679
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	B:C0042679
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	B:C0348016
vincristine	O
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	B:C0042679
50μg	O
(	O
Vin50	O
-	O
IV	O
)	O
.	O

When	O
volume	O
reached	O
>	O
250	O
mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug	O
-	O
free	O
silk	O
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	I:C0013089
-	O
F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	O
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	B:C0042679
-	O
IV	O
)	O
.	O

IC50	O
for	O
vincristine	B:C0042679
and	O
doxorubicin	O
was	O
0.5ng	O
/	O
mL	O
and	O
200ng	O
/	O
mL	O
,	O
respectively	O
.	O

IC50	O
for	O
vincristine	O
and	O
doxorubicin	B:C0013089
was	O
0.5ng	O
/	O
mL	O
and	O
200ng	O
/	O
mL	O
,	O
respectively	O
.	O

There	O
was	O
no	O
difference	O
between	O
Dox400	B:C0013089
-	O
F	O
[	O
6	O
±	O

Vin50	B:C0042679
-F	O
(	O
12.4±3.5	O
DTEP	O
)	O
had	O
slower	O
growth	I:C4086857
compared	O
to	O
Control	O
-	O
F	O
(	O
p<0.001	O
)	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
Vin50	O
-F	O
and	O
Vin50	O
-	O
IV	O
(	O
14±0	O
DTEP	O
)	O
.	O

Vin50	O
-F	O
(	O
12.4±3.5	O
DTEP	O
)	O
had	O
slower	B:C4086857
growth	I:C4086857
compared	O
to	O
Control	O
-	O
F	O
(	O
p<0.001	O
)	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
Vin50	O
-F	O
and	O
Vin50	O
-	O
IV	O
(	O
14±0	O
DTEP	O
)	O
.	O

Vin50	O
-F	O
(	O
12.4±3.5	O
DTEP	O
)	O
had	O
slower	O
growth	I:C4086857
compared	O
to	O
Control	O
-	O
F	O
(	O
p<0.001	O
)	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
Vin50	B:C0042679
-F	O
and	O
Vin50	O
-	O
IV	O
(	O
14±0	O
DTEP	O
)	O
.	O

Vin50	O
-F	O
(	O
12.4±3.5	O
DTEP	O
)	O
had	O
slower	O
growth	I:C4086857
compared	O
to	O
Control	O
-	O
F	O
(	O
p<0.001	O
)	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
Vin50	O
-F	O
and	O
Vin50	B:C0042679
-	O
IV	O
(	O
14±0	O
DTEP	O
)	O
.	O

Growth	B:C4086857
was	I:C4086857
slowest	I:C4086857
with	O
Vin50	O
-G	O
,	O
28±10.3	O
DTEP	O
compared	O
to	O
all	O
other	O
treatment	O
groups	O
(	O
p<0.05	O
)	O
.	O

Growth	O
was	I:C4086857
slowest	I:C4086857
with	O
Vin50	B:C0042679
-G	O
,	O
28±10.3	O
DTEP	O
compared	O
to	O
all	O
other	O
treatment	O
groups	O
(	O
p<0.05	O
)	O
.	O

Sustained	B:C1710261
delivery	I:C1710261
of	O
vincristine	O
inside	O
the	O
sarcoma	O
tumor	O
with	O
silk	O
gel	O
decreased	O
tumor	O
growth	O
.	O

Sustained	O
delivery	I:C1710261
of	O
vincristine	B:C0042679
inside	O
the	O
sarcoma	O
tumor	O
with	O
silk	O
gel	O
decreased	O
tumor	O
growth	O
.	O

Sustained	O
delivery	I:C1710261
of	O
vincristine	O
inside	O
the	O
sarcoma	B:C1261473
tumor	O
with	O
silk	O
gel	O
decreased	O
tumor	O
growth	O
.	O

Sustained	O
delivery	I:C1710261
of	O
vincristine	O
inside	O
the	O
sarcoma	O
tumor	B:C0027651
with	O
silk	O
gel	O
decreased	O
tumor	O
growth	O
.	O

Sustained	O
delivery	I:C1710261
of	O
vincristine	O
inside	O
the	O
sarcoma	O
tumor	O
with	O
silk	B:C0074529
gel	O
decreased	O
tumor	O
growth	O
.	O

Applying	O
this	O
intratumoral	B:C1831733
treatment	I:C1831733
strategy	O
may	O
potentially	O
decrease	O
the	O
extent	O
of	O
surgical	O
excision	I:C0728940
.	O

Applying	O
this	O
intratumoral	O
treatment	I:C1831733
strategy	O
may	O
potentially	O
decrease	O
the	O
extent	O
of	O
surgical	B:C0728940
excision	I:C0728940
.	O

